Pharmaceutical companies should take note as pharmacies are becoming more and more a “one-stop” shop for the health and wellness needs of patients, according to a recent McCann Health white paper. The research focuses on the fact that, as pharmacies become the preferred choice for patients’ healthcare needs, pharmaceutical companies should realize that pharmacists are healthcare professionals who are highly …
Laser Or CIJ Coding Can Help Deter Growing Counterfeit Drugs Problem
Recently the DEA has issued warnings regarding counterfeit pills, particularly those used in pain management. A CNN report revealed that pill presses, used in producing counterfeit pills that often contain the deadly drug fentanyl, are reaching our country’s border in record numbers. In fact, customs agents claim the rate at which they are seizing the presses is 19 times higher …
Coding And Marking Benefits Consumers And Brands In Pharmaceutical
As a pharmaceutical manufacturer, you may think coding and marking systems are error-prone and at many times difficult to manage. Whether for printing barcodes, 2D codes, expiration dates, lot codes, Data Matrix codes or other data, the pharmaceutical industry is one in which reliable coding is a must, not an option. Counterfeiting has been a huge concern in the pharmaceutical …
Fidia Pharmaceutical Introduces New Packaging For Hyalo Gyn®
Recently it was announced that a global leader in hyaluronic acid products, Fidia Farmaceutical S.p.a. and its wholly owned subsidiary Fidia Pharma USA Inc., introduced new product packaging for its HYALO GYN® vaginal hydrating gel, while the formulation of the product would remain the same. The company specializes in R & D and manufacturing of products based on HA, or …
Pharma News – Novartis Acquires Selexys Pharmaceuticals
Recently in pharma news it was announced that Basel, Switzerland-based Novartis, a global healthcare company, has acquired Oklahoma City-based Selexys Pharmaceuticals, a company specializing in inflammatory and hematological disorders, for $665 million. According to news reports, Selexys was purchased following a Phase II trial focusing on the use of the anti-P-selectin antibody SelG1 for reducing the instance of vaso-occlusive crises …